Brian Kaider has represented Fortune 500 corporations and has consulted on various litigations involving complex technical and scientific issues, including:
Kenneth Lo has conducted numerous due diligence reviews and related negotiations that resulted in several multi-million dollar transactions, including:
- An environmental litigation involving agrochemical contamination of municipal drinking water. Brian helped shape the factual and legal strategy for the health-effects portion of the case and took a lead role in developing a team of 31 world-renowned scientists and physicians as expert witnesses. The outstanding expert reports that resulted from this endeavor played a key role in forcing the manufacturer of the chemical at issue to settle the case for $105,000,000. As a result, the water districts serving six Midwestern states will receive funds necessary to purchase filters, ensuring safe drinking water to 38 million residents.
- A patent litigation involving matching software for business applications. Brian developed the invalidity positions that formed the basis for a successful summary judgment motion.
Kenneth Lo has conducted numerous due diligence reviews and related negotiations that resulted in several multi-million dollar transactions, including:
- A joint development and exclusive commercialization licensing agreement between Takeda Pharmaceutical Company and Dainippon Sumitomo Pharmaceutical Company related to lurasidone for use in treating schizophrenia and bipolar disorder. The agreement stipulates that Takeda makes an upfront payment of 10 billion Japanese Yen and milestone payments of about $180 million USD for regulatory filing and approval for the targeted indications, as well as royalty payments based on net sales.
- An exclusive development and commercialization licensing agreement between Takeda Pharmaceutical Company and Intra-Cellular Therapies, Inc. related to phosphodiesterase-1 (PDE-1) inhibitors for treating schizophrenia. Under the terms of the agreement, Takeda will pay about $500 million USD in the aggregate for upfront and development milestones, and up to an additional $250 million USD for achieving certain sales-based milestones, along with tiered royalty payments based on net sales.
- A development and commercialization licensing agreement between Takeda Pharmaceutical Company and AMAG Pharmaceuticals related to ferumoxytol injection to treat iron deficiency anemia. The agreement terms include an upfront payment of $60 million USD and up to $220 million USD in development and commercialization milestones.
- An exclusive licensing agreement between Takeda Pharmaceutical Company and Zinfandel Pharmaceuticals to validate and use a biomarker for the risk Alzheimer’s disease in combination with pioglitazone. Under the terms of the agreement, Takeda will pay about $87 million USD in the aggregate for upfront and development milestones.
- A broad strategic alliance between Forest Laboratories Inc. and Moksha8 to commercialize vilazodone and other Forest products in Latin America. The agreement stipulates that Forest provides up to $125 million USD over a 2 year period based on milestones reached with an option to acquire Moksha8 after the 2 year period.
